44 Women’s Hormonal Health Statistics – Essential Facts Every Woman Should Know in 2026

Comprehensive data compiled from extensive research on women’s hormonal health conditions, treatments, and outcomes

Key Takeaways

• You’re facing a widespread health crisis – Over 190 million women worldwide struggle with endometriosis, while 1 in 10 face PCOS, and 1 in 8 develop thyroid disorders, creating a massive burden on women’s health
• Hormonal conditions remain severely underdiagnosed – Up to 70% of PCOS cases and 60% of thyroid disorders go undiagnosed, with women visiting 3+ providers before receiving proper care
• Treatment gaps persist despite proven therapies – Less than 4% of eligible women use hormone therapy despite 90% experiencing symptom relief, while vaginal estrogen remains particularly underutilized
• The healthcare system needs improvement – With many OB/GYNs lacking specialized menopause training and 21% of women feeling dismissed by providers, systemic changes are urgently needed
• Economic impacts are staggering – From the $8 billion annual cost of PCOS to the $26.6 billion loss from menopause symptoms, hormonal health significantly affects both personal finances and the broader economy
• Diagnostic delays cause unnecessary suffering – Average time to endometriosis diagnosis is 7-12 years, while 47% of women visit multiple providers before proper diagnosis
• Multiple conditions often overlap – Women with PCOS face higher diabetes risk, thyroid dysfunction increases gestational diabetes risk, and hormonal imbalances cascade through multiple systems
• Hope exists through proper treatment – When appropriately diagnosed and treated, hormonal conditions are highly manageable, with HRT particularly effective for multiple symptoms including bone health and cardiovascular protection

Understanding the Scope

1. 1 in 8 women will develop a thyroid disorder during her lifetime

The American Thyroid Association reports that women are five to eight times more likely than men to have thyroid problems, with one woman in eight developing a thyroid disorder during her lifetime. This staggering prevalence means thyroid dysfunction affects more women than breast cancer. The gender disparity is attributed to hormonal fluctuations during pregnancy, menopause, and throughout the menstrual cycle that make women’s thyroid glands more vulnerable. Understanding this risk can encourage proactive screening and early intervention. Source: American Thyroid Association – General Information

2. 6-13% of reproductive-aged women have PCOS, but 70% remain undiagnosed

Polycystic ovary syndrome affects an estimated 6-13% of reproductive-aged women globally, yet up to 70% of affected women remain undiagnosed worldwide. This massive diagnostic gap means millions of women struggle with symptoms like irregular periods, excess hair growth, and infertility without understanding the cause. The variation in prevalence reflects differences in diagnostic criteria and population characteristics. Early diagnosis and treatment are crucial for preventing long-term complications including diabetes and cardiovascular disease. Source: WHO – Polycystic Ovary Syndrome Fact Sheet

3. 190 million women globally are affected by endometriosis

Endometriosis affects roughly 10% of reproductive-age women and girls globally, totaling approximately 190 million individuals. This chronic disease causes severe, life-impacting pain during periods, sexual intercourse, and bowel movements, significantly affecting quality of life. Despite its prevalence rivaling that of diabetes, endometriosis receives far less public attention and research funding. The condition’s impact extends beyond physical symptoms to affect mental health, relationships, and career prospects. Source: WHO – Endometriosis Fact Sheet

4. 1 in 6 couples globally experience infertility

The WHO reports that approximately 17.5% of the adult population – roughly 1 in 6 people – experience infertility at some point. This translates to millions of couples facing the emotional and financial burden of difficulty conceiving. In about one-third of cases, the cause is female factor infertility, often related to hormonal imbalances, ovulation disorders, or conditions like PCOS and endometriosis. The prevalence is consistent across countries regardless of income level, highlighting infertility as a global health issue. Source: WHO – 1 in 6 People Globally Affected by Infertility

Thyroid Disorders

5. 12% of the U.S. population will develop a thyroid condition

More than 12% of the U.S. population will develop a thyroid condition during their lifetime, with an estimated 20 million Americans currently having some form of thyroid disease. This high prevalence makes thyroid disorders one of the most common endocrine conditions. Up to 60% of those with thyroid disease are unaware of their condition, leading to years of unexplained symptoms. The economic burden includes both direct medical costs and indirect costs from lost productivity and reduced quality of life. Source: American Thyroid Association – Prevalence and Impact

6. Hypothyroidism affects approximately 4.6% of the U.S. population

Recent data shows hypothyroidism prevalence affects approximately 4.6% of Americans, representing over 15 million people with this condition. This reflects both better diagnostic capabilities and potentially increasing environmental and lifestyle factors affecting thyroid health. Levothyroxine, the primary treatment for hypothyroidism, consistently ranks among the most prescribed medications in the United States, highlighting the condition’s widespread impact. The prevalence particularly affects women, who are 8-9 times more likely to develop hypothyroidism compared to men. Source: American Thyroid Association – Hypothyroidism Statistics

7. Women are 5-8 times more likely to have thyroid problems than men

The gender disparity in thyroid disease is striking, with women being five to eight times more likely than men to develop thyroid problems. This increased susceptibility is attributed to estrogen’s effects on thyroid hormone metabolism and autoimmune responses. Women are particularly vulnerable during times of hormonal change including puberty, pregnancy, and menopause. The higher prevalence in women necessitates increased awareness and screening, particularly during reproductive years. Source: American Thyroid Association – Gender Differences

8. 40-50% of women develop hypothyroidism after head/neck radiation therapy

Studies show that 40-50% of women who receive head or neck radiation develop hypothyroidism within several years of treatment. This high rate highlights the thyroid gland’s sensitivity to radiation and the importance of long-term monitoring for cancer survivors. The risk extends to medical radiation exposure from diagnostic procedures, emphasizing the need for thyroid protection during imaging studies. Regular screening allows for early detection and treatment, preventing the complications of untreated hypothyroidism. Source: BJOG – Management of Thyroid Disorders in Pregnancy

9. Up to 60% of thyroid disease cases remain undiagnosed

Despite affecting millions, up to 60% of people with thyroid disease are unaware of their condition. This diagnostic gap leads to years of unexplained symptoms including fatigue, weight changes, depression, and cognitive difficulties. The nonspecific nature of thyroid symptoms often leads to misdiagnosis or dismissal as “normal aging” or stress. Improved awareness and routine screening could identify millions of cases, allowing for treatment that dramatically improves quality of life. Source: American Thyroid Association – Undiagnosed Cases

Polycystic Ovary Syndrome (PCOS)

10. PCOS is the most common cause of anovulation and infertility

PCOS is recognized as the most common cause of anovulation and a leading cause of infertility in women. The condition disrupts normal ovulation, making conception difficult without treatment. Up to 70% of women with PCOS experience infertility issues, though many can conceive with appropriate interventions including ovulation induction medications or assisted reproductive technologies. Early diagnosis and treatment significantly improve fertility outcomes, emphasizing the importance of recognizing PCOS symptoms in women trying to conceive. Source: WHO – PCOS and Infertility

11. PCOS prevalence varies significantly by ethnicity

PCOS prevalence shows variation by ethnicity, with rates typically ranging from 3% to 10% in most populations, though some specific ethnic groups may show higher prevalence. Middle Eastern, South Asian, and Mediterranean women tend to have higher rates compared to East Asian populations. These differences reflect both genetic susceptibility and environmental factors including diet and lifestyle. Understanding ethnic variations helps tailor screening and treatment approaches for different populations. Source: NCBI – Ethnic Variations in PCOS

12. Many women with PCOS report reduced quality of life

The impact of PCOS extends beyond physical symptoms, with studies showing significant quality of life impacts in affected women. This reflects the condition’s effects on multiple aspects of wellbeing including body image, fertility concerns, and metabolic health. Women with PCOS are more likely to experience depression (37% vs 14.2% in those without) and anxiety (42% vs 8.5%). The psychological burden often goes unaddressed in medical care, highlighting the need for comprehensive treatment approaches. Source: WHO – PCOS Impact on Quality of Life

13. Healthcare costs for PCOS estimated at $8 billion annually

As of 2020, healthcare costs associated with PCOS were estimated at $8 billion in the United States alone. These costs stem from diagnosis, pregnancy-related expenses, and the higher risk of chronic conditions including diabetes and cardiovascular disease. Individual women face significant out-of-pocket expenses for fertility treatments often not covered by insurance. The economic burden underscores PCOS as not just a personal health issue but a significant public health concern. Source: NCBI – Economic Burden of PCOS

14. Women with type 2 diabetes have higher rates of PCOS

Research shows that women with type 2 diabetes, particularly those diagnosed at younger ages, have higher rates of PCOS, highlighting the strong metabolic connection between these conditions. This bidirectional relationship means PCOS increases diabetes risk while diabetes can worsen PCOS symptoms. The overlap necessitates screening for PCOS in young women with diabetes and vice versa. Early intervention in adolescence can prevent or delay the progression of both conditions. Source: NCBI – PCOS and Diabetes Connection

Endometriosis

15. Average time to diagnosis is 7-12 years from symptom onset

Women with endometriosis face diagnostic delays between 3.5 and 13 years, with most experiencing 7-12 years of symptoms before receiving a proper diagnosis. This devastating delay results from normalization of menstrual pain, lack of awareness among healthcare providers, and the need for surgical confirmation. During this time, women suffer unnecessarily while the disease progresses, potentially affecting fertility and quality of life. The delay is often longer for younger women whose symptoms are dismissed as “normal” period pain. Source: International Journal of Gynecology & Obstetrics – Endometriosis Prevalence

16. 31% of women with infertility have endometriosis

Meta-analysis data reveals that 31% of women with infertility have endometriosis, while 42% of those with chronic pelvic pain are affected. This high prevalence among women seeking fertility treatment highlights endometriosis as a major cause of reproductive challenges. The condition can affect fertility through multiple mechanisms including anatomical distortion, inflammation, and altered egg quality. Understanding this connection is crucial for appropriate fertility counseling and treatment planning. Source: PMC – Systematic Review on Endometriosis Prevalence

17. Total annual cost per woman with endometriosis is €9,579

A large multicenter study found the total cost per woman with endometriosis is €9,579 annually, with €6,298 attributable to lost work productivity. This economic burden rivals that of other chronic diseases like diabetes and heart disease. Women often reduce work hours, change careers, or leave the workforce entirely due to debilitating symptoms. The financial impact extends to partners and families, creating a ripple effect throughout society. Source: IJGO – Economic Burden of Endometriosis

18. Prevalence peaks between ages 25-29

Global burden of disease data shows endometriosis prevalence peaks between ages 25 and 29, affecting women during prime reproductive and career-building years. The condition maintains high prevalence through ages 30-39 before dropping rapidly after age 40. This timing creates maximum disruption to education, career advancement, and family planning. Understanding age-specific prevalence helps target screening and support services to those most at risk. Source: European Journal of Obstetrics & Gynecology – Global Burden Study

19. 24-50% of women with endometriosis experience infertility

Between 24% and 50% of women with endometriosis face infertility challenges, making it one of the most common causes of difficulty conceiving. The wide range reflects varying disease severity and individual factors. Endometriosis can impair fertility through fallopian tube damage, ovarian cysts, and inflammatory factors affecting egg quality and implantation. However, many women with endometriosis can conceive with appropriate treatment, offering hope despite the diagnosis. Source: Johns Hopkins Medicine – Endometriosis and Fertility

Menopause and Hormone Therapy

20. Less than 4% of eligible women currently use hormone therapy

Despite being the most effective treatment for menopausal symptoms, HRT usage dropped from 27% in 1999 to less than 4% today. This dramatic decline followed controversial study results that created lasting fear about hormone therapy risks. The tragedy is that 90% of women report significant symptom relief within 2 months of individualized treatment. Vaginal estrogen, particularly safe and effective for genitourinary symptoms, remains especially underutilized despite minimal systemic absorption. Source: Medscape – Hormone Therapy at Historic Lows

21. 70-80% of menopausal women experience symptoms affecting quality of life

An estimated 70% to 80% of women experience menopause symptoms that adversely affect their quality of life and productivity. Hot flashes alone affect women for an average of 7-11 years, with 40% of women in their 60s and 10-15% in their 70s continuing to experience them. These symptoms extend beyond vasomotor issues to include sleep disruption, mood changes, cognitive difficulties, and genitourinary syndrome. The widespread impact on daily functioning makes menopause a significant public health issue deserving of better treatment access. Source: The Menopause Society – HRT Usage Rates

22. 88% of women using HRT choose transdermal over oral forms

Recent data shows nearly 88% of women use transdermal estrogen patches or gels rather than oral pills, with less than 5% using synthetic progestins. This shift reflects growing awareness that transdermal delivery avoids first-pass liver metabolism, reducing risks of blood clots and other complications. The preference for bioidentical hormones over synthetic alternatives represents a move toward more physiologic hormone replacement. These safer delivery methods and formulations should reassure women considering HRT. Source: The Menopause Society – HRT Formulation Trends

23. Estrogen therapy reduces mortality risk by 19% when continued after 65

A landmark 2024 study found that estrogen monotherapy beyond age 65 was associated with 19% reduction in mortality, along with reduced risks of breast cancer (16%), lung cancer (13%), colorectal cancer (12%), and dementia (2%). These findings challenge previous assumptions about age limits for hormone therapy. The benefits were particularly pronounced with low-dose vaginal or transdermal preparations using estradiol rather than conjugated estrogens. This data supports individualized decision-making rather than arbitrary age cutoffs for HRT discontinuation. Source: PubMed – Menopausal Hormone Therapy Beyond Age 65

24. Only 20.7% of women seek medical help for perimenopause symptoms

Despite high symptom prevalence, only 20.7% of U.S. women consult medical professionals about perimenopause according to a 2024 study of 4,432 women. Among those who do seek help, 70.8% are correctly identified as perimenopausal, leaving nearly 30% without proper diagnosis. Women average 4-5 healthcare visits before receiving appropriate treatment, with half waiting 6 months with life-disrupting symptoms before seeking care. This massive treatment gap reflects both patient and provider barriers to menopause care. Source: Nature – Healthcare Seeking in U.S. Women

Infertility and Reproductive Hormones

25. 40% of female infertility cases involve ovulation disorders

The most common cause of female infertility is not ovulating, occurring in 40% of women with infertility. These ovulation disorders often stem from hormonal imbalances including PCOS, thyroid dysfunction, or hypothalamic amenorrhea. Many ovulation disorders are treatable with medications like clomiphene citrate or letrozole, offering hope for conception. Understanding ovulation as the primary fertility issue emphasizes the importance of hormonal evaluation in fertility workups. Source: Cofertility – Fertility Statistics

26. Female fertility begins declining at age 30

Research confirms that female fertility begins to decline at 30 years of age, with more rapid decline after 35 and significant reduction after 40. This age-related decline reflects both decreased egg quantity and quality, with chromosomal abnormalities increasing with maternal age. Women are increasingly delaying childbearing for educational and career reasons, making age-related fertility decline a growing concern. Understanding fertility timelines helps women make informed decisions about family planning and potential fertility preservation. Source: SingleCare – Infertility Statistics

27. IVF success requires an average of 2.5 cycles

The average number of IVF cycles needed to achieve pregnancy is 2.5, highlighting that success rarely comes with the first attempt. This reality affects both emotional wellbeing and financial planning, as each cycle can cost $12,000-$20,000. The cumulative success rate improves with multiple cycles, offering hope to those who don’t succeed initially. Understanding the typical journey helps couples set realistic expectations and plan accordingly. Source: SingleCare – IVF Success Rates

28. 12% of all IVF cycles use donor eggs

Approximately 12% of all IVF cycles in the U.S. involve eggs retrieved from a donor, reflecting the growing acceptance and success of third-party reproduction. Donor egg IVF offers hope to women with diminished ovarian reserve, genetic conditions, or repeated IVF failures with their own eggs. Success rates with donor eggs remain high regardless of recipient age, as the eggs come from young, healthy donors. This option has enabled thousands of women to experience pregnancy and childbirth despite their own fertility challenges. Source: Cofertility – Egg Donation Statistics

29. 85-90% of infertility cases are treated with conventional therapies

Contrary to popular belief, 85% to 90% of infertility cases are treated with conventional medical therapies such as medication or surgery, not IVF. These less invasive treatments include ovulation induction, intrauterine insemination, and surgical correction of anatomical issues. Many couples conceive with simple interventions like thyroid hormone replacement or metformin for PCOS. This statistic offers hope that fertility treatment doesn’t always mean expensive, complex procedures. Source: Cofertility – Infertility Treatment Options

Pregnancy and Hormonal Conditions

30. 10-20% of pregnant women develop thyroid dysfunction

Between 10% and 20% of pregnant women experience thyroid dysfunction during pregnancy, with implications for both maternal and fetal health. Untreated hypothyroidism increases risks of miscarriage, preterm delivery, and neurodevelopmental problems in offspring. The physiological changes of pregnancy stress the thyroid gland, unmasking subclinical disease. Universal screening remains controversial, but high-risk women should be tested early in pregnancy. Source: Journal of Clinical Endocrinology & Metabolism – Thyroid in Pregnancy

31. 14% of pregnancies globally are affected by gestational diabetes

Gestational diabetes affects approximately 14% of pregnancies worldwide, posing risks to both mothers and babies. Women with GDM face increased risks of type 2 diabetes, with up to 50% developing it within 5-10 years postpartum. The condition also increases risks of macrosomia, birth complications, and metabolic disorders in offspring. Rising obesity rates and older maternal age contribute to increasing GDM prevalence globally. Source: SAGE Journals – Vitamin A and Gestational Diabetes

32. Women with hypothyroidism have higher risk of gestational diabetes

Studies show women with hypothyroidism face significantly increased risk of developing gestational diabetes, with higher TSH levels correlating with greater GDM risk. This connection reflects the thyroid’s role in glucose metabolism and insulin sensitivity. The overlap necessitates careful monitoring of both thyroid function and glucose levels during pregnancy. Early thyroid treatment may help reduce GDM risk, emphasizing the importance of preconception thyroid optimization. Source: American Thyroid Association – Thyroid and GDM Connection

33. 10-60% of women develop permanent hypothyroidism after postpartum thyroiditis

Following postpartum thyroiditis, 10% of women remain permanently hypothyroid immediately, while 20-30% develop it within 3-5 years and 50-60% by 8-10 years. This high progression rate makes postpartum thyroiditis a significant risk factor for lifelong thyroid disease. Women with thyroid antibodies face even higher risk of progression. Long-term monitoring is essential for all women who experience postpartum thyroiditis to ensure timely treatment if permanent hypothyroidism develops. Source: BJOG – Management of Thyroid Disorders

34. Vitamin A deficiency linked to both GDM and thyroid dysfunction

Recent research reveals vitamin A deficiency may be associated with prevalent endocrinopathies during pregnancy, including both gestational diabetes and thyroid dysfunction. Vitamin A plays crucial roles in glucose homeostasis and insulin sensitivity, with deficiency potentially contributing to metabolic disturbances. This connection suggests nutritional optimization before and during pregnancy could help prevent hormonal complications. Understanding these nutritional links opens new avenues for prevention rather than just treatment. Source: SAGE – Vitamin A and Pregnancy Endocrinopathies

Bone Health and Osteoporosis

35. 1 in 3 women over 50 will experience an osteoporotic fracture

The International Osteoporosis Foundation reports that one in three women over the age of 50 worldwide will experience an osteoporotic fracture in their lifetime. This staggering statistic makes osteoporosis a major public health concern affecting millions. Hip fractures are particularly devastating, with 60% of women losing independent walking ability and 25% dying within one year. The personal and societal costs of these fractures emphasize the critical importance of bone health maintenance and early intervention. Source: IOF – Epidemiology of Osteoporosis

36. Up to 20% of bone loss occurs during menopause

Research indicates that up to 20% of bone loss can happen during a woman’s menopause journey, with most occurring in the first 5-7 years after menopause. This rapid bone loss results from declining estrogen levels, which normally help prevent bone breakdown. Without intervention, this accelerated loss significantly increases fracture risk in later years. Hormone therapy, particularly when initiated early in menopause, can prevent much of this bone loss, protecting long-term skeletal health. Source: Endocrine Society – Menopause and Bone Loss

37. 9.1 million U.S. women have osteoporosis, 26 million have low bone mass

The National Osteoporosis Foundation estimates there are 9.1 million women with osteoporosis and an additional 26 million with low bone mass in the United States. This means over 35 million American women are at increased fracture risk. The prevalence increases dramatically with age, affecting two-thirds of women over 90. These numbers are expected to rise with population aging, making osteoporosis prevention and treatment increasingly important public health priorities. Source: PMC – Primary Osteoporosis in Postmenopausal Women

38. Osteoporosis accounts for more hospital days than diabetes, MI, and breast cancer

In women over 45, osteoporosis accounts for more days spent in hospital than many other diseases including diabetes, myocardial infarction, and breast cancer. This reflects both the high incidence of osteoporotic fractures and their serious complications requiring extended care. The healthcare burden extends beyond acute treatment to rehabilitation and long-term care needs. Understanding osteoporosis’s healthcare impact emphasizes its importance relative to other conditions receiving more public attention. Source: IOF – Healthcare Impact of Osteoporosis

39. 30% reduction in hip fractures possible with 10% increase in peak bone mass

Research shows that hip fractures could be reduced by 30% with an increase in peak bone mass of 10%. Peak bone mass, achieved in the mid-twenties for spine and hip, provides the foundation for lifelong bone health. Optimizing bone mass accrual through adequate nutrition, exercise, and hormone balance during adolescence and young adulthood offers powerful fracture prevention. This highlights the importance of bone health education and interventions beginning in youth, not just after menopause. Source: PMC – Peak Bone Mass and Fracture Prevention

Healthcare Access and Disparities

40. Many OB/GYNs lack specialized menopause training

Studies indicate that many OB/GYNs report inadequate training in menopause management, with only a limited percentage of residency programs offering comprehensive menopause education. This educational gap leaves millions of women without access to knowledgeable providers during a critical life transition. The shortage is even more severe for certified menopause specialists, with only about 3,000 serving millions of menopausal U.S. women. Medical education reform is urgently needed to address this gap in women’s healthcare. Source: Axios – Menopause Training in Medical Education

41. 21% of women feel their hormonal concerns are dismissed by providers

About 21% of women feel their hormonal concerns are dismissed by healthcare providers, discouraging them from seeking further medical care. This dismissal creates barriers to proper diagnosis and treatment, prolonging suffering unnecessarily. Women report being told symptoms are “normal,” “just stress,” or “all in your head” rather than receiving appropriate evaluation. Provider education about women’s hormonal health and improved communication skills are essential for rebuilding trust. Source: Mira Fertility – Hormonal Health Report 2025

42. Black women experience hot flashes for 10 years vs 6.5 for White women

Significant racial disparities exist in menopausal symptoms, with Black women experiencing hot flashes for an average of 10 years compared to 6.5 years for White women. Overall, 80% of Black women experience hot flashes versus 65% of White women. Despite more severe symptoms, Black women are 26% less likely to be prescribed hormone therapy. These disparities reflect both biological differences and systemic healthcare inequities requiring targeted interventions. Source: Healthline – Racial Disparities in Menopause

43. 32% of women hesitate to address hormonal issues due to costs

Financial barriers significantly impact hormonal healthcare, with nearly a third of women (32%),hesitating to address hormonal issues due to costs. This barrier is especially significant for menopausal women, who face costs about 45% higher than average. Many hormonal treatments, particularly fertility services and some hormone therapies, lack insurance coverage. Affordable healthcare solutions and wider insurance coverage are crucial to removing these financial barriers. Source: Mira Fertility – Cost Barriers Report

44. 37% of women travel over 10 miles for hormonal healthcare

Geographic barriers affect access, with nearly 37% of women traveling more than 10 miles to access hormonal healthcare services. This particularly affects rural communities where specialist care is scarce. Travel requirements create additional burdens of time, cost, and logistics, especially for those needing frequent monitoring. Telemedicine and local provider education could help bridge these geographic gaps in care. Source: Mira Fertility – Healthcare Access Report

The Bottom Line

These statistics paint a comprehensive picture of women’s hormonal health – a landscape marked by high prevalence, significant underdiagnosis, treatment gaps, and systemic healthcare challenges. From the 1 in 8 women who will develop thyroid disorders to the 1 in 3 who will experience osteoporotic fractures, hormonal conditions affect virtually every woman at some point in her life.

The path forward requires systemic change: improved medical education, especially regarding menopause and hormonal health; increased access to evidence-based treatments like hormone therapy, particularly vaginal estrogen; reduced diagnostic delays through better awareness and screening protocols; and addressing the racial, geographic, and economic disparities that prevent equitable care.

Perhaps most importantly, these statistics remind us that hormonal health is not a niche women’s issue but a mainstream healthcare priority affecting billions globally. With proper diagnosis and treatment, most hormonal conditions are highly manageable. The tragedy lies not in the conditions themselves but in the unnecessary suffering caused by underdiagnosis, undertreatment, and dismissal of women’s concerns. Every woman deserves access to knowledgeable providers, evidence-based treatments, and compassionate care throughout her hormonal journey.

Sources Used

1. American Thyroid Association – General Information and Press Room
2. World Health Organization – Polycystic Ovary Syndrome Fact Sheet
3. World Health Organization – Endometriosis Fact Sheet
4. The Menopause Society – Hormone Therapy Position Statements
5. International Osteoporosis Foundation – Epidemiology and Statistics
6. Nature – Healthcare Seeking Patterns in U.S. Women
7. Journal of Clinical Endocrinology & Metabolism – Pregnancy Guidelines
8. Mira Fertility – 2025 Women’s Hormonal Health Report
9. Cofertility – Comprehensive Fertility Statistics
10. PubMed Central – Multiple Peer-Reviewed Studies
11. Axios – Healthcare Provider Training Analysis
12. International Journal of Gynecology & Obstetrics – Endometriosis Studies
13. Endocrine Society – Patient Education Resources
14. Johns Hopkins Medicine – Women’s Health Information
15. SingleCare – Infertility and Healthcare Statistics